NCT03258359View on ClinicalTrials.gov

Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Myelodysplastic Syndromes
Interventions
BIOLOGICAL

PACTN

To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.

Trial Locations (1)

92093

University of California, San Diego, San Diego

Sponsors

Lead Sponsor

PersImmune, Inc
All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

PersImmune, Inc

INDUSTRY